MindRank raised $52 million in Series B funding to advance MDR-001, its oral GLP-1 candidate, with Phase III in China already underway. The company said the money will scale its AI-native Molecule Arts Platform and support multiple preclinical and clinical programs tied to cardiometabolic disease. The funding highlights intensifying competition to move GLP-1 therapies beyond injections, with companies seeking oral convenience while maintaining the class’s efficacy and safety signals. With MDR-001 entering Phase III, MindRank is betting its computational workflow can shorten the path from candidate selection to pivotal execution.